TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CanSino Biologics, Inc. Class H ( (HK:6185) ) just unveiled an update.
CanSino Biologics Inc. has announced its 2025 second extraordinary general meeting, where significant amendments to corporate governance policies and the company’s Articles of Association will be discussed. The meeting will also address the appointment of new independent non-executive directors and the utilization of reserves to offset losses, indicating a strategic move to strengthen its governance framework and financial stability.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$64.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, focusing on the development and production of vaccines. It operates in the pharmaceutical industry, primarily targeting infectious diseases with innovative vaccine solutions.
Average Trading Volume: 1,504,905
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.36B
Find detailed analytics on 6185 stock on TipRanks’ Stock Analysis page.